REG - Conygar Investmnt Co - Planning Application for the Island Quarter

Conygar Investment CoAnnouncement

02/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221202:nRSB3524Ia&default-theme=true

RNS Number : 3524I  Conygar Investment Company PLC(The)  02 December 2022

 

 

 [2nd December 2022]

THE CONYGAR INVESTMENT COMPANY PLC

Planning application for bioscience accommodation

at The Island Quarter, Nottingham

The Conygar Investment Company PLC ("Conygar") has submitted a detailed
application for the next phase of The Island Quarter development in
Nottingham. The application comprises a 23,123 sq.m. (249,000 sq.ft.)
bioscience building, which includes both laboratory and office space.

Christopher Ware, Property Director of Conygar, commented:

"We are delighted to submit this application for the next phase of
development. Nottingham is already home to a large number of exciting
businesses in the bioscience space and this scheme will be an excellent
addition to the mixed-use development we are creating at The Island Quarter".

Enquiries:

The Conygar Investment Company PLC

Christopher Ware: 020 7258 8670

Liberum Capital Limited (Nominated Adviser and Broker)

Richard Lindley: 020 3100 2185

Temple Bar Advisory (Public Relations)

Alex Child-Villiers: 07795 425580

William Barker: 07827 960151

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFSIFUFEESEEE